Cystic fibrosis has a history stretching back centuries, from cryptic folklore warnings about salty-skinned children to a 2019 triple-combination therapy that transformed the disease from a childhood death sentence into a manageable chronic condition. The story of CF is one of medicine’s most dramatic arcs: a disease that killed most children before age five in the 1950s now has a predicted median survival approaching 50 years.
Salty Skin and Medieval Warnings
Long before anyone understood the biology, families across Europe recognized that something was terribly wrong with children whose skin tasted unusually salty. As far back as the 15th century, a European proverb warned: “Woe to the child who tastes salty from a kiss on the brow, for he is cursed and soon will die.” The salt on a child’s skin was seen as a death omen, and for good reason. Without any understanding of the disease or treatment, these children invariably died young from lung infections and malnutrition. The saltiness, we now know, comes from a defective protein that disrupts the body’s ability to move salt and water across cell membranes, leading to abnormally salty sweat.
Dorothy Andersen Names the Disease
Cystic fibrosis wasn’t formally described until 1938, when Dorothy Andersen, a pathologist at Columbia University’s Babies Hospital in New York, published a landmark paper titled “Cystic Fibrosis of the Pancreas and Its Relation to Celiac Disease.” Andersen had been performing autopsies on infants and young children and noticed a pattern: damaged, cyst-riddled pancreases in children who had died with symptoms resembling celiac disease, including stunted growth, distended bellies, and pale, foul-smelling stools. These children couldn’t digest food properly because their pancreases were destroyed by thick, sticky mucus.
Her paper gave the disease its name, drawn from the fibrous cysts she found in the pancreas. At the time, the disease was understood primarily as a digestive problem. It would take years before doctors fully grasped that the lungs were equally affected and that thick mucus clogging the airways was ultimately what killed most patients.
Mucoviscidosis and the Bigger Picture
In 1945, pathologist Sydney Farber proposed that cystic fibrosis wasn’t just a pancreatic problem but a systemic disease affecting mucus production throughout the body. He coined the term “mucoviscidosis,” meaning viscous mucus, to reflect this broader understanding. The name caught on in many European countries and is still used in parts of the world today, though “cystic fibrosis” became the dominant term in English-speaking medicine.
Farber’s insight was critical. It shifted medical thinking from viewing CF as a localized organ disease to recognizing it as a whole-body condition affecting the lungs, sinuses, digestive tract, and reproductive system. That shift opened the door to treatments targeting multiple organ systems rather than the pancreas alone.
The Sweat Test and Early Treatment
A major diagnostic breakthrough came in the 1950s when Paul di Sant’Agnese discovered that children with CF had abnormally high levels of salt in their sweat. This observation, rooted in the same phenomenon medieval families had noticed on their children’s foreheads, led to the development of the sweat chloride test, which remains the gold standard for CF diagnosis today.
Treatment in this era was rudimentary but evolving. Pancreatic enzyme supplements helped children absorb nutrients from food, addressing the severe malnutrition that had killed many patients in infancy. By the 1980s, enteric-coated microspheres replaced earlier enzyme tablets. These tiny capsules emptied into the small intestine at the same rate as food, dramatically improving fat absorption, reducing abdominal pain, and cutting down on the frequent, greasy bowel movements that plagued patients. Better nutrition meant stronger bodies that could fight lung infections longer.
Even so, the prognosis remained grim. In 1954, the median survival age for a child with CF was just four to five years.
Finding the Gene
The genetic cause of cystic fibrosis was identified in 1989, when a collaboration led by researchers at the Hospital for Sick Children in Toronto pinpointed a single gene on chromosome 7. This gene, called CFTR, contains the instructions for building a protein that acts as a channel for chloride ions (a component of salt) to move in and out of cells. When the gene is defective, that channel malfunctions. The result is thick, dehydrated mucus in the lungs, pancreas, and other organs.
The discovery was a watershed moment. For the first time, scientists understood the molecular root of a disease that had been killing children for centuries. It also revealed that CF is a recessive genetic condition: a child must inherit a faulty copy of the CFTR gene from both parents to develop the disease. More than 2,000 different mutations in the CFTR gene have since been identified, which explains why CF varies so much in severity from person to person.
Initially, many researchers hoped gene therapy would provide a cure, replacing the broken gene with a working copy. That approach proved far more difficult than expected and has yet to succeed clinically. But the discovery of the gene opened a different path: designing drugs that fix or compensate for the defective protein itself.
The First Modulator Drug
It took more than two decades to translate the genetic discovery into a targeted therapy. In 2012, the FDA approved ivacaftor (sold as Kalydeco), the first drug designed to treat the underlying cause of CF rather than just managing symptoms. Ivacaftor works by helping the defective CFTR protein channel open properly, restoring some of the salt and water flow that CF disrupts.
The catch: ivacaftor only worked for patients carrying specific, relatively rare mutations, most notably the G551D mutation. That meant only about 4 to 5 percent of the CF population initially benefited. Still, the proof of concept was extraordinary. For those patients, lung function improved measurably, sweat chloride levels dropped, and weight gain followed. It showed that the defective protein could be pharmacologically rescued.
Trikafta Changes Everything
The real transformation came in 2019 with the approval of a triple-combination therapy (elexacaftor, tezacaftor, and ivacaftor, sold as Trikafta). Unlike earlier modulators, this combination works for roughly 90 percent of people with CF, specifically those carrying at least one copy of the most common CFTR mutation.
The clinical results were striking. Within four weeks, patients saw an average improvement of about 9 percentage points in lung function as measured by the volume of air they could forcefully exhale in one second. By 24 weeks, that improvement grew to nearly 13 percentage points. For context, a gain of that size can mean the difference between needing supplemental oxygen and exercising comfortably, or between qualifying for a lung transplant list and no longer needing one.
Beyond the numbers, patients reported dramatic quality-of-life changes: less coughing, fewer lung infections, reduced time spent on daily airway clearance routines, and weight gain. Some described it as breathing freely for the first time in their lives.
How Survival Has Changed
The progress in CF survival over the past seven decades is one of the most remarkable stories in modern medicine. In 1954, most children with the disease died before kindergarten, with a median survival of four to five years. By 2019, the Cystic Fibrosis Foundation estimated that a child born that year with CF could expect to live to about 48 years. That number is almost certainly still climbing as the effects of modulator therapies accumulate in registry data.
This improvement didn’t come from a single breakthrough. It was layered: better nutrition through enzyme therapy, aggressive treatment of lung infections with antibiotics, specialized CF care centers that standardized best practices, newborn screening programs that caught the disease earlier, and finally, modulator drugs that address the root molecular defect. Each advance built on the last, turning a disease that was once invisible in the medical literature into one of the best examples of how basic science translates into real gains in human lifespan.